<DOC>
	<DOCNO>NCT00111813</DOCNO>
	<brief_summary>The purpose study : - To determine maximum tolerate dose ( MTD ) combination oral vorinostat bortezomib participant advance multiple myeloma - To assess safety tolerability regimen document participant 's clinical status ( anti-tumor activity ) combination , determine per standard care .</brief_summary>
	<brief_title>Phase 1 Study Vorinostat Bortezomib Multiple Myeloma ( MK-0683-015 EXT 1 ( AM1 ) )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Adults refractory relapse multiple myeloma Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( measurement determine participant 's ability perform daily activity ) Adequate bone marrow reserve Adequate hepatic renal function Ability swallow capsule 3 week since prior chemotherapy recover prior toxicity Participants plan bone marrow transplant within 4 week start treatment Participants prior treatment investigational agent similar antitumor mechanism Participants active/uncontrolled clinically significant illness Pregnant nursing female participant Participants receive bortezomib within 3 month start trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>